ALK and IGF-1R as independent targets in crizotinib resistant lung cancer

Abstract ALK positive non-small cell lung cancer is highly responsive to ALK inhibitors such as crizotinib, but drug resistance typically develops within a year of treatment. In this study we investigated whether IGF-1R is an independent druggable target in ALK-positive lung cancer cells. We confirm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christabel Wilson, Mhairi Nimick, Hayley Nehoff, John C. Ashton
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/398999e043dc426f9106b6eb7c119b5d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!